Your browser doesn't support javascript.
Tobacco smoking changes during the first pre-vaccination phases of the COVID-19 pandemic: A systematic review and meta-analysis.
Sarich, Peter; Cabasag, Citadel J; Liebermann, Erica; Vaneckova, Pavla; Carle, Chelsea; Hughes, Suzanne; Egger, Sam; O'Connell, Dianne L; Weber, Marianne F; da Costa, Allini Mafra; Caruana, Michael; Bray, Freddie; Canfell, Karen; Ginsburg, Ophira; Steinberg, Julia; Soerjomataram, Isabelle.
  • Sarich P; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • Cabasag CJ; Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
  • Liebermann E; College of Nursing, University of Rhode Island, RI, United States.
  • Vaneckova P; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • Carle C; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • Hughes S; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • Egger S; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • O'Connell DL; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • Weber MF; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • da Costa AM; Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
  • Caruana M; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • Bray F; Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
  • Canfell K; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • Ginsburg O; Center for Global Health, National Cancer Institute, MD, United States.
  • Steinberg J; The Daffodil Centre, The University of Sydney, A Joint Venture with Cancer Council NSW, PO Box 572, Kings Cross, NSW 1340, Australia.
  • Soerjomataram I; Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
EClinicalMedicine ; 47: 101375, 2022 May.
Article in English | MEDLINE | ID: covidwho-1783295
ABSTRACT

Background:

Globally, tobacco smoking remains the largest preventable cause of premature death. The COVID-19 pandemic has forced nations to take unprecedented measures, including 'lockdowns' that might impact tobacco smoking behaviour. We performed a systematic review and meta-analyses to assess smoking behaviour changes during the early pre-vaccination phases of the COVID-19 pandemic in 2020.

Methods:

We searched Medline/Embase/PsycINFO/BioRxiv/MedRxiv/SSRN databases (January-November 2020) for published and pre-print articles that reported specific smoking behaviour changes or intentions after the onset of the COVID-19 pandemic. We used random-effects models to pool prevalence ratios comparing the prevalence of smoking during and before the pandemic, and the prevalence of smoking behaviour changes during the pandemic. The PROSPERO registration number for this systematic review was CRD42020206383.

Findings:

31 studies were included in meta-analyses, with smoking data for 269,164 participants across 24 countries. The proportion of people smoking during the pandemic was lower than that before, with a pooled prevalence ratio of 0·87 (95%CI0·79-0·97). Among people who smoke, 21% (95%CI14-30%) smoked less, 27% (95%CI22-32%) smoked more, 50% (95%CI41%-58%) had unchanged smoking and 4% (95%CI1-9%) reported quitting smoking. Among people who did not smoke, 2% (95%CI1-3%) started smoking during the pandemic. Heterogeneity was high in all meta-analyses and so the pooled estimates should be interpreted with caution (I2 >91% and p-heterogeneity<0·001). Almost all studies were at high risk of bias due to use of non-representative samples, non-response bias, and utilisation of non-validated questions.

Interpretation:

Smoking behaviour changes during the first phases of the COVID-19 pandemic in 2020 were highly mixed. Meta-analyses indicated that there was a relative reduction in overall smoking prevalence during the pandemic, while similar proportions of people who smoke smoked more or smoked less, although heterogeneity was high. Implementation of evidence-based tobacco control policies and programs, including tobacco cessation services, have an important role in ensuring that the COVID-19 pandemic does not exacerbate the smoking pandemic and associated adverse health outcomes.

Funding:

No specific funding was received for this study.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Vaccines Language: English Journal: EClinicalMedicine Year: 2022 Document Type: Article Affiliation country: J.eclinm.2022.101375

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Vaccines Language: English Journal: EClinicalMedicine Year: 2022 Document Type: Article Affiliation country: J.eclinm.2022.101375